Cambridge 7 Tesla Cerebral Small Vessel Disease Study

Imaging the Arterial Pathology in Cerebral Small Vessel Disease Using 7 Tesla Magnetic Resonance Imaging

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04330222

Acronym

CamSVD

Enrollment

210

Registered

2020-04-01

Start date

2020-03-09

Completion date

2024-01-12

Last updated

2022-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral Small Vessel Diseases, Cerebral Small Vessel Ischemic Disease, Lacunar Stroke

Keywords

Vascular Cognitive Impairment, Vascular Dementia, 7 Tesla Magnetic Resonance Imagine (7T MRI)

Brief summary

CamSVD is jointly sponsored by the University of Cambridge and Cambridge University Hospitals NHS Foundation Trust. We aim to explore and understand the underlying arterial pathology in Cerebral Small Vessel Disease (SVD) using ultra-high-field 7 Tesla MRI. We will optimise 7T Time-of-Flight MR angiography, blood suppressed MR sequence and phase-contrast (PC) MR angiography for visualization of perforating lenticulostriate arteries. This optimised sequences will be used to determine the range of arterial pathologies seen in individuals presenting with lacunar strokes. The pathologies of the perforating lenticulostriate arteries will be correlated with conventional clinical risk factors, cognition and radiological markers of SVD.

Interventions

DIAGNOSTIC_TEST7 Tesla Magnetic Resonance Imaging

Diagnostic Imaging

OTHERBrief Memory and Executive Test

Cognitive Assessment

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 99 Years

Healthy volunteers

Yes

Inclusion criteria

1\. Symptomatic lacunar stroke with corresponding lacunar infarct on MRI

Exclusion criteria

1. Unable/unwilling to consent; 2. Age\<18; 3. Stroke aetiology due to cardio-embolism or large vessel disease; 4. Lacunar infarcts \>1.5cm; 5. Severe stroke (NIHSS score ≥16); 6. Evidence of cortical infarct of any size; 7. Other major neurological diseases; 8. Severe systemic diseases such as heart failure, liver failure and kidney failure or any illness in the judgement of the investigator that could affect participation in the study; 9. MRI contraindications e.g. metal objects in or on the body, claustrophobia, pregnancy, known allergy to gadolinium containing contrast agent, impaired renal function with estimated glomerular filtration rate (eGFR) \<59ml/min/1.73m2.

Design outcomes

Primary

Measure	Time frame
Range and pattern of pathology seen in the perforating arteries like presence or absence of focal atheroma and narrowing	March 2020-

Secondary

Measure	Time frame
Differences in morphology of perforating arteries between SVD patients and healthy volunteers	March 2020-
Correlation of morphology of perforating arteries with cardiovascular risk factors and radiological markers of SVD	March 2020-

Countries

United Kingdom

Contacts

Primary ContactStefania Nannoni, MD

sn572@medschl.cam.ac.uk01223 216 509

Backup ContactChristopher Osuafor, MBBS

co400@cam.ac.uk01223 274 383

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026